NCT06326684View on ClinicalTrials.gov

Suvorexant and Alcohol

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 7, 2024

Primary Completion Date

March 15, 2027

Study Completion Date

March 15, 2027

Conditions
Alcohol Use Disorder
Interventions
DRUG

Alcohol

The pharmacodynamic effects of alcohol (0.2 and 0.4 g/kg) will be determined.

DRUG

Placebo

The effects of placebo will be determined.

DRUG

Suvorexant

The effects of suvorexant dose 1 will be determined.

DRUG

Suvorexant

The effects of suvorexant dose 2 will be determined.

Trial Locations (1)

40507

RECRUITING

Psychopharmacology of Addiction Laboratory, Lexington

All Listed Sponsors
collaborator

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

NIH

lead

University of Kentucky

OTHER